China's Bloomage Forms Botox JV with Medytox of South Korea

Bloomage BioTechnology formed a JV with South Korea's Medytox to market Mediytox's version of the wrinkle treatment Botox (Botulinum Toxin) in China. The JV, which will be owned 50-50 by the two partners, will be called Medybloom. Bloomage is already involved in China's aesthetic care market as a producer of hyaluronic acid. It markets various grades of HA in China as orthopedic injections, ophthalmic solutions, cosmetic fillers, surgical anti-adhesion products and food supplements. More details.... Stock Symbols: (HK: 00963) (KS: 086900) Share this with colleagues: // //